ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GHF Greenhouse

6.625
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Greenhouse LSE:GHF London Ordinary Share GB00B0T2CP59 PARTCIPATING SHS NPV
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 6.625 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
  -
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 6.625 GBX

Greenhouse Fund (GHF) Latest News

Real-Time news about Greenhouse (London Stock Exchange): 0 recent articles

Greenhouse Fund (GHF) Discussions and Chat

Greenhouse Fund Forums and Chat

Date Time Title Posts
16/7/200814:53THE GREENHOUSE FUND..all your green eggs in one basket29

Add a New Thread

Greenhouse Fund (GHF) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Greenhouse Fund (GHF) Top Chat Posts

Top Posts
Posted at 16/7/2008 14:53 by reckless_rat
a tidying up job. Molectra tried and failed to raise new funding in its own right last winter and seemingly again more recently. GHF were left with little option but to take full control or face writing off their investment. Going to be a long slog from here, with all eggs in one basket.
Posted at 01/4/2008 06:21 by steve3005
topvest - I tend to agree. Even if the Bauxol stuff comes to zilch (which I feel won't be the case) the Molectra investment is worth more than the current share price, which even with it's recent uptick is still below NAV.
Posted at 23/3/2008 05:04 by steve3005
No that's not the reason, the products from the recycling have been flagged very clearly and will never be anything other than mundane stuff - but the market is crying out for the main products (steel, crumb rubber). And as pointed out in my post GHF I think will be on a p/e of just 7 later this year, and is now trading on less than nav?
Posted at 25/2/2008 09:22 by steve3005
Here are my jottings on the GHF. As usual DYO research, this isn't a recommendation to invest etc.

Disclosure - I hold shares in GHF and in Virotec.

There is little news flow (even the 2007 interims aren't on the website)
The shares are v tightly held – 10 holders account for 75%, 28 holders account for 98% so maybe that's why there is no news – word of mouth will suffice!
Virotec holds 19.3% - no sell off of this holding, they hit Hydrodec instead for some more cash.
Notable investors include David Gaskell the funds investment advisor (10%), Nigel Wray (resigned as a director but didn't sell off his shareholding of 7.5m shares).
I'm puzzled by the comment that 66.3m shares (42%) not in public hands – being held by insiders?
Fund is trading at close to its NAV, probably due to lack of news flow.
IMHO a downside is that Brian Sheeran is Chairman now Wray has gone – the only thing Brian has done as far as I can tell (IMHO) in Virotec is draw down a huge salary while destroying shareholder value. Please let me know if I'm wrong here and I will apologise effusively for my comment. The good thing is the Board of the fund is capped in how much they can charge, so no massive cheques for no ascertainable value a la Virotec.
Elsiva invested in 10m shares in 9/07
What's the company done?
1. Invested in Molectra – it now hold 58% of company.
Also advanced a loan of AU$4.5m to secure land for building full plant. (No news on progress can be found).
There is a massive worldwide problem with used tyres, Molectra technology recovers 100% of tyre, and even uses some of the by products to power the plant!
Proven technology in pilot plant.
Currently consumers pay levy to dispose of tyres so raw materials will be free if not an additional flow of cash.
Molectra reckons on getting AU$5.40 (£2.50) value per tyre, not clear if this is gross or net - it comes from a comment from the inventor of the process.
Greenhouse says the Wiley report (can't find this published anywhere) suggests for the new large scale process plant:
Capex = £6m
Process costs: 2.6m tyres (26,000 tons @£70/ton) = £1,8m
Income (from Molectra comment) = (2.6m*£2.50) = £6.5m
Gross profit = 4.7m
Less capex writedown expenses etc say £1m
Net = 3.7m
Greenhouse entitled to 58%, so with 155m shares that = 1.38pps. So at 10p a share for GHF = P/E of 7 just from initial stage of Molectra
Rights to Molectra technology have been sold to 19 countries - not sure on what terms.

2. Invested £570k plus GHF shares (hence 19% shareholding by Virotec) in non-core Bauxol technology from Virotech, carrying this investment at £6m in balance sheet. Very quiet on development progress. Maybe something will be announced in annual accounts?

Last accounts:
Assets = £13m
Shares = 155m
NAV = 8.4pps
Share price this morning 8.6p

Interesting company!
Posted at 15/5/2007 11:58 by clusium
Assuming spinning out the Milectra business makes a whole lot for GHF, is this the crucially advantageous time to buy? Or is having some Virotec, with its c19% holding and other activities enough?
Posted at 06/5/2007 20:10 by edale
Looking at the preliminary report there are only 74 shareholders in GHF. I would have thought an unusually small number. Are we the wise few or the foolish few ? With such a small number of investors presumably this means the shares are tightly held and any positive change in sentiment could lead to a rapid increase in share price.I guess only time will tell although Molectra does look to have great potential.
Posted at 07/1/2007 22:44 by edale
I keep looking for an update on the performance of the scaled up Molectra plant trials which I believe should be available sometime in the first quarter. This looks very interesting technology and successful plant trials leading to take up of plants round the world would be a major boost for GHF although I guess could short term call up more capital.
Posted at 29/6/2006 13:27 by brazil1970
This looks like good news...

Greenhouse Fund Limited (The)
29 June 2006



For immediate release 29 June 2006



The Greenhouse Fund Limited

("Greenhouse" or "the Company")

Licence Acquisitions



THE GREENHOUSE FUND ACQUISITION OF BAUXSOL SUB-LICENSES AND OTHER TECHNOLOGIES
FROM VIROTEC INTERNATIONAL


Greenhouse today announces the acquisition of five Bauxsol technology
sub-licences and the purchase of the assets of Sterling Environmental Solutions
(together the "Transaction") from Virotec International Ltd ("Virotec"). It is
intended that Brian Sheeran, Virotec Executive Chairman, be appointed to the
board of Greenhouse to oversee commercialisation of these technologies.


The aggregate consideration for the above transactions is GBP5 million, to be
satisfied by the issue of 30,000,000 new shares in Greenhouse ("Shares") and a
further GBP500,000 in cash. At the opening price on 29 June 2006 of 15p, the Share
element is valued at GBP4,500,000. As a result of the issue of the Shares, Virotec
will have a 19 per cent. holding in the voting share capital of Greenhouse. An
application has today been made for the Shares to be admitted to trading on AIM
and it is expected that the Shares will be admitted to trading on 5 July 2006.


Background to the Transaction


The five technologies being sub-licenced to Greenhouse are Bauxsol platform
technologies developed by Virotec. These are:


(a) ViroConcrete Technology, speciality cement products with applications in
shotcreteing, grouting, high density concrete, acid exposed concrete or
concretes that are exposed to water or wet environments, particularly salt water
environments;

(b) ViroAirFilter Technology, designed to remove mercury, CO2 and other
polluting metals from industrial flue gasses by 'gas scrubbing' such
environmentally hazardous compounds from waste gases prior to their release into
the atmosphere;

(c) ViroFertiliser Technology, aims to control the level of phosphate pollution
and increase crop yields via the slow release of phosphate from superphosphate
fertilisers;

(d) Gastric animal applications; aims to relieve chronic and potentially life
threatening gastric problems within animals; and

(e) Any further new commercial applications developed from the Bauxsol
technology; giving Greenhouse access to the time and efforts of the two main
scientists, their facilities and staff involved in the development of Bauxsol
and its applications in the Southern Cross University in New South Wales,
Australia.


The intellectual property rights of the above technologies are either held
directly by the Virotec Group or licensed to it by Nauveau Technology
Investments Limited, a company outside the Virotec Group and is ultimately owned
by either Nauveau Technology Investments Ltd or another entity, Mount Aspiring
Geochemistry Limited, a company outside the Virotec Group.


Greenhouse has established a wholly-owned subsidiary company, Greenhouse IP
Development Limited, to hold the sub-licences and to develop the related
technologies.


The strategy is to further develop the technologies, using both academic and
commercial partners from within industry. Once an application has been fully
commercialised, Greenhouse will consider the strategic options available to
maximise shareholder value. Such alternatives include introducing a new
structure for each license, depending on the particular market and opportunity
that it faces.


In addition, as part of the Transaction, Greenhouse has, through another wholly
owned subsidiary (Greenhouse Organic Solutions Limited), purchased the assets of
Sterling Environmental Solutions Ltd ("Sterling"), a UK non-trading company with
a view to establishing a regional treatment centre ("RTC") for the treatment of
high strength organic waste streams. The assets acquired include all
intellectual property rights owned or used by Sterling, including all rights
relating to the concept for the treatment of industrial waste at a central
treatment centre or RTC. Sterling has no trading revenue and has not filed any
audited accounts.


In addition, it is intended that Greenhouse will enter into a 12 month option to
acquire the business and assets of ImperativePlus Pty Ltd, a wholly owned
subsidiary of Virotec. It has been agreed in principle that Greenhouse will pay
a nominal consideration on grant and on exercise of this option.


Greenhouse Chairman Nigel Wray commented, "This is a very exciting transaction
for Greenhouse, coming less than six months since its launch on AIM. We believe
that Bauxsol is a tremendous technology and provides a platform for a range of
applications; each of the applications we have licenced has the potential to
become a significant business in its own right. Greenhouse will also work with
Virotec and our research team to create further new Bauxsol applications. I look
forward to announcing developments as Greenhouse works on the applications and
partners with academic and industry research bodies to further the commercial
development of these technologies."


For further information please contact:


Paul Gazzard,
Greenhouse Advisor Ltd.
Tel: 020 7355 7600
Email: pg@greenhousefund.co.uk

Charles Ryland/Ben Willey
Buchanan Communications
Tel: 020 7466 5000
Greenhouse Fund share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock